Skip to content
2000
image of MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years

Abstract

Background

The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a promising and innovative approach, demonstrating favorable clinical potential in the treatment of these disorders. Although preliminary studies have confirmed its therapeutic efficacy, a comprehensive and systematic analysis of the research trends and current limitations of MDMA-AT remains lacking.

Methods

This study employed a bibliometric approach to systematically retrieve and analyze research literature published between 1994 and 2023 on the application of MDMA in the treatment of PTSD, anxiety, and depression. Relevant data were obtained from three prominent databases: Web of Science Core Collection, PubMed, and Scopus. VOSviewer and Microsoft Excel were used to perform visual and quantitative analyses, focusing on publication trends, research hotspots, prolific authors, leading institutions, and international collaboration networks.

Results

The findings indicated a substantial increase in MDMA-related research over the past decade. The United States has led the field in publication output, with the Multidisciplinary Association for Psychedelic Studies (MAPS) identified as the most productive institution. Key figures, such as Rick Doblin, have demonstrated high influence and centrality within the global research network. The research focus has gradually shifted from investigations of the neurotoxic properties of MDMA to explorations of its therapeutic mechanisms, safety profiles, and clinical applications.

Conclusion

This study provides a comprehensive synthesis of the past thirty years of research on MDMA-AT in the treatment of PTSD, anxiety, and depression, identifying major research trajectories and critical challenges in the field. While current findings highlight the therapeutic promise of MDMA and its translational potential, further research is needed to improve trial design, enhance sample diversity, and evaluate long-term effects in order to support the standardization and evidence-based integration of MDMA-assisted therapy into clinical practice.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673359474250511181821
2025-06-02
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673359474250511181821
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Schäfer S.K. Thomas L.M. Lindner S. Lieb K. World Health Organization’s low-intensity psychosocial interventions: a systematic review and meta-analysis of the effects of Problem Management Plus and Step-by-Step. World Psychiatry 2023 22 3 449 462 10.1002/wps.21129 37713578
    [Google Scholar]
  2. Pariante C.M. Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008 31 9 464 468 10.1016/j.tins.2008.06.006 18675469
    [Google Scholar]
  3. Balducci C. Frasca A. Zotti M. La Vitola P. Mhillaj E. Grigoli E. Iacobellis M. Grandi F. Messa M. Colombo L. Molteni M. Trabace L. Rossetti C. Salmona M. Forloni G. Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer’s disease. Brain Behav. Immun. 2017 60 188 197 27751869
    [Google Scholar]
  4. Wang H. Xiao L. Wang H. Wang G. Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive- like behavior in a depressive-like adult male rat model. Physiol. Behav. 2020 215 112749 31770536
    [Google Scholar]
  5. Pfefferbaum B. Posttraumatic stress disorder in children in the context of the COVID-19 pandemic. J. Am. Acad. Child Adolesc. Psychiatry 2022 61 8 957 959 35219806
    [Google Scholar]
  6. Wade D.M. Brewin C.R. Howell D.C. White E. Mythen M.G. Weinman J.A. Intrusive memories of hallucinations and delusions in traumatized intensive care patients: An interview study. Br. J. Health Psychol. 2015 20 3 613 631 24944013
    [Google Scholar]
  7. Brewin C.R. Gregory J.D. Lipton M. Burgess N. Intrusive images in psychological disorders: Characteristics, neural mechanisms, and treatment implications. Psychol. Rev. 2010 117 1 210 232 10.1037/a0018113 20063969
    [Google Scholar]
  8. Zerbinatti C.V. Wahrle S.E. Kim H. Cam J.A. Bales K. Paul S.M. Holtzman D.M. Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J. Biol. Chem. 2006 281 47 36180 36186 10.1074/jbc.M604436200 17012232
    [Google Scholar]
  9. Nath S. Agholme L. Kurudenkandy F.R. Granseth B. Marcusson J. Hallbeck M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid. J. Neurosci. 2012 32 26 8767 8777 10.1523/JNEUROSCI.0615‑12.2012 22745479
    [Google Scholar]
  10. Yang W.N. Ma K.G. Qian Y.H. Zhang J.S. Feng G.F. Shi L.L. Zhang Z.C. Liu Z.H. Mitogen-activated protein kinase signaling pathways promote low-density lipoprotein receptor-related protein 1-mediated internalization of beta-amyloid protein in primary cortical neurons. Int. J. Biochem. Cell Biol. 2015 64 252 264 10.1016/j.biocel.2015.04.013 25936756
    [Google Scholar]
  11. Patton S.C. Watkins L.E. Killeen T.K. Hien D.A. Posttraumatic stress disorder and substance use disorder screening, assessment, and treatment. Curr. Psychiatry Rep. 2024 26 12 843 851 10.1007/s11920‑024‑01547‑8 39407067
    [Google Scholar]
  12. Zhu Y. Jha S.C. Shutta K.H. Huang T. Balasubramanian R. Clish C.B. Hankinson S.E. Kubzansky L.D. Psychological distress and metabolomic markers: A systematic review of posttraumatic stress disorder, anxiety, and subclinical distress. Neurosci. Biobehav. Rev. 2022 143 104954 10.1016/j.neubiorev.2022.104954 36368524
    [Google Scholar]
  13. Cohen B.E. Edmondson D. Kronish I.M. State of the art review: Depression, stress, anxiety, and cardiovascular disease. Am. J. Hypertens. 2015 28 11 1295 1302 10.1093/ajh/hpv047 25911639
    [Google Scholar]
  14. Zoladz P.R. Diamond D.M. Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature. Neurosci. Biobehav. Rev. 2013 37 5 860 895 10.1016/j.neubiorev.2013.03.024 23567521
    [Google Scholar]
  15. Adamec R. Holmes A. Blundell J. Vulnerability to lasting anxiogenic effects of brief exposure to predator stimuli: sex, serotonin and other factors-relevance to PTSD. Neurosci. Biobehav. Rev. 2008 32 7 1287 1292 18550167
    [Google Scholar]
  16. Li M. Yang X.K. Yang J. Li T.X. Cui C. Peng X. Lei J. Ren K. Ming J. Zhang P. Tian B. Ketamine ameliorates post-traumatic social avoidance by erasing the traumatic memory encoded in VTA-innervated BLA engram cells. Neuron 2024 112 18 3192 3210.e6 39032491
    [Google Scholar]
  17. Norred M.A. Zuschlag Z.D. Hamner M.B. A neuroanatomic and pathophysiologic framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder. Drugs 2024 84 2 149 164 38413493
    [Google Scholar]
  18. Yazar-Klosinski B.B. Mithoefer M.C. Potential Psychiatric Uses for MDMA. Clin. Pharmacol. Ther. 2017 101 2 194 196 27859039
    [Google Scholar]
  19. Healy D. Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol. Psychiatr. Sci. 2024 33 e40 39289881
    [Google Scholar]
  20. Heinz M.V. Yom-Tov E. Mackin D.M. Matsumura R. Jacobson N.C. A large-scale observational comparison of antidepressants and their effects. J. Psychiatr. Res. 2024 178 219 224 39163659
    [Google Scholar]
  21. Slomski A. MDMA-assisted therapy highly effective for PTSD. JAMA 2021 326 4 299 34313690
    [Google Scholar]
  22. Geller J. Whitney E. Therapeutic potential of MDMA- and psychedelic-assisted psychotherapy for adolescent depression and trauma. Curr. Psychiatry Rep. 2024 39699759
    [Google Scholar]
  23. Kangaslampi S. Zijlmans J. MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations. Eur. Child Adolesc. Psychiatry 2024 33 11 3753 3764 37814082
    [Google Scholar]
  24. Mithoefer M.C. Wagner M.T. Mithoefer A.T. Jerome L. Doblin R. The safety and efficacy of +/-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacol. 2011 25 4 439 452 20643699
    [Google Scholar]
  25. Mithoefer M.C. Feduccia A.A. Jerome L. Mithoefer A. Wagner M. Walsh Z. Hamilton S. Yazar-Klosinski B. Emerson A. Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl.) 2019 236 9 2735 2745 31065731
    [Google Scholar]
  26. Mithoefer M.C. Grob C.S. Brewerton T.D. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 2016 3 5 481 488 27067625
    [Google Scholar]
  27. Danforth A.L. Struble C.M. Yazar-Klosinski B. Grob C.S. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016 64 237 249 25818246
    [Google Scholar]
  28. Wolfgang A.S. Fonzo G.A. Gray J.C. Krystal J.H. Grzenda A. Widge A.S. Kraguljac N.V. McDonald W.M. Rodriguez C.I. Nemeroff C.B. MDMA and MDMA-Assisted Therapy. Am. J. Psychiatry 2025 182 1 79 103 10.1176/appi.ajp.20230681 39741438
    [Google Scholar]
  29. de la Torre R. Farré M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci. 2004 25 10 505 508 10.1016/j.tips.2004.08.001 15380932
    [Google Scholar]
  30. He X. Leng Z. Li H. Wang D. Cao K. Olfactory ensheathing cell transplantation for spinal cord injury: An 18-year bibliometric analysis based on the Web of Science. Neural Regen. Res. 2013 8 14 1286 1296 10.4103/1673‑5374.121630 25206423
    [Google Scholar]
  31. Alotaibi N.M. Nassiri F. Badhiwala J.H. Witiw C.D. Ibrahim G.M. Macdonald R.L. Lozano A.M. The most cited works in aneurysmal subarachnoid hemorrhage: A bibliometric analysis of the 100 most cited articles. World Neurosurg. 2016 89 587 592.e6 10.1016/j.wneu.2015.11.072 26723285
    [Google Scholar]
  32. Wang Y. Chen Q. Dang X. Lu W. Zhang X. Yan H. Niu S. Yan X. Yan J. A bibliometric analysis on traumatic brain injury in forensic medicine of a half-century (1972–2021). Front. Neurol. 2023 14 913855 10.3389/fneur.2023.913855 36816552
    [Google Scholar]
  33. Chen C. Song M. Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS One 2019 14 10 e0223994 10.1371/journal.pone.0223994 31671124
    [Google Scholar]
  34. Ye S. Hu J. Liu Z. Liang M. Progress and Research Trends on Catha edulis (Vahl) Endl. (Catha edulis): A Review and Bibliometric Analysis. Front. Pharmacol. 2021 12 705376 10.3389/fphar.2021.705376 34867319
    [Google Scholar]
  35. O’Donnell J. Gladden R.M. Mattson C.L. Hunter C.T. Davis N.L. Vital Signs: Characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the district of columbia, January–June 2019. MMWR Morb. Mortal. Wkly. Rep. 2020 69 35 1189 1197 10.15585/mmwr.mm6935a1 32881854
    [Google Scholar]
  36. Mithoefer M.C. Mithoefer A.T. Feduccia A.A. Jerome L. Wagner M. Wymer J. Holland J. Hamilton S. Yazar-Klosinski B. Emerson A. Doblin R. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post- traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 2018 5 6 486 497 10.1016/S2215‑0366(18)30135‑4 29728331
    [Google Scholar]
  37. Mitchell J.M. Ot’alora G M. van der Kolk B. Shannon S. Bogenschutz M. Gelfand Y. Paleos C. Nicholas C.R. Quevedo S. Balliett B. Hamilton S. Mithoefer M. Kleiman S. Parker-Guilbert K. Tzarfaty K. Harrison C. de Boer A. Doblin R. Yazar-Klosinski B. Harrison C. Yazar-Klosinski B. Garas W. May D. Marta C. Walker S. Nielson E. Wells G. Brown R. Amiaz R. Wallach Y. Worthy R. Lilienstein A. Emerson A. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat. Med. 2023 29 10 2473 2480 10.1038/s41591‑023‑02565‑4 37709999
    [Google Scholar]
  38. Mithoefer M.C. Wagner M.T. Mithoefer A.T. Jerome L. Martin S.F. Yazar-Klosinski B. Michel Y. Brewerton T.D. Doblin R. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J. Psychopharmacol. 2013 27 1 28 39 10.1177/0269881112456611 23172889
    [Google Scholar]
  39. Siegel A.N. Meshkat S. Benitah K. Lipsitz O. Gill H. Lui L.M.W. Teopiz K.M. McIntyre R.S. Rosenblat J.D. Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J. Psychiatr. Res. 2021 139 71 81 34048997
    [Google Scholar]
  40. Bedi G. Cotton S.M. Guerin A.A. Jackson H.J. MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail. Aust. N. Z. J. Psychiatry 2023 57 4 476 481 36165006
    [Google Scholar]
  41. Danforth A.L. Grob C.S. Struble C. Feduccia A.A. Walker N. Jerome L. Yazar-Klosinski B. Emerson A. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl.) 2018 235 11 3137 3148 30196397
    [Google Scholar]
  42. Wolfson P.E. Andries J. Feduccia A.A. Jerome L. Wang J.B. Williams E. Carlin S.C. Sola E. Hamilton S. Yazar-Klosinski B. Emerson A. Mithoefer M.C. Doblin R. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci. Rep. 2020 10 1 20442 33235285
    [Google Scholar]
  43. Sessa B. Higbed L. O’Brien S. Durant C. Sakal C. Titheradge D. Williams T.M. Rose-Morris A. Brew-Girard E. Burrows S. Wiseman C. Wilson S. Rickard J. Nutt D.J. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J. Psychopharmacol. 2021 35 4 375 383 33601929
    [Google Scholar]
  44. Green A.R. Mechan A.O. Elliott J.M. O’Shea E. Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol. Rev. 2003 55 3 463 508 12869661
    [Google Scholar]
  45. Moratalla R. Khairnar A. Simola N. Granado N. García-Montes J.R. Porceddu P.F. Tizabi Y. Costa G. Morelli M. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog. Neurobiol. 2017 155 149 170 26455459
    [Google Scholar]
  46. Baumann M.H. Wang X. Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl.) 2007 189 4 407 424 16541247
    [Google Scholar]
  47. Stone D.M. Hanson G.R. Gibb J.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 1987 26 11 1657 1661 2448703
    [Google Scholar]
  48. Mueller F. Lenz C. Steiner M. Dolder P.C. Walter M. Lang U.E. Liechti M.E. Borgwardt S. Neuroimaging in moderate MDMA use: A systematic review. Neurosci. Biobehav. Rev. 2016 62 21 34 26746590
    [Google Scholar]
  49. Liechti M.E. Baumann C. Gamma A. Vollenweider F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000 22 5 513 521 10731626
    [Google Scholar]
  50. O’Shea E. Esteban B. Camarero J. Green A.R. Colado M.I. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 2001 40 1 65 74 11077072
    [Google Scholar]
  51. Vizeli P. Liechti M.E. No influence of dopamine system gene variations on acute effects of MDMA. Front. Psychiatry 2019 10 755 31708815
    [Google Scholar]
  52. Vegting Y. Reneman L. Booij J. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology (Berl.) 2016 233 19-20 3473 3501 27568200
    [Google Scholar]
  53. Kivell B. Day D. Bosch P. Schenk S. Miller J. MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation. Neuroscience 2010 168 1 82 95 20298763
    [Google Scholar]
  54. Biezonski D.K. Meyer J.S. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. J. Neurochem. 2010 112 4 951 962 20002520
    [Google Scholar]
  55. Green A.R. Gabrielsson J. Marsden C.A. Fone K.C. MDMA: on the translation from rodent to human dosing. Psychopharmacology (Berl.) 2009 204 2 375 378 19139850
    [Google Scholar]
  56. Nutt D. King L.A. Saulsbury W. Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007 369 9566 1047 1053 17382831
    [Google Scholar]
  57. Nutt D.J. King L.A. Phillips L.D. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010 376 9752 1558 1565 21036393
    [Google Scholar]
  58. Vakde T. Diaz M. Uday K. Duncalf R. Rapidly reversible multiorgan failure after ingestion of “Molly” (pure 3,4-methylenedioxymethamphetamine): a case report. J. Med. Case Rep. 2014 8 204 24942782
    [Google Scholar]
  59. Connolly E. O’Callaghan G. MDMA toxicity presenting with severe hyperpyrexia: a case report. Crit. Care Resusc. 1999 1 4 368 370 16599881
    [Google Scholar]
  60. Ghaffari-Rafi A. Eum K.S. Villanueva J. Jahanmir J. Protracted hyperthermia and delayed rhabdomyolysis in ecstasy toxicity. Medicine (Baltimore) 2020 99 41 e21842 10.1097/MD.0000000000021842 33031256
    [Google Scholar]
  61. Holze F. Vizeli P. Müller F. Ley L. Duerig R. Varghese N. Eckert A. Borgwardt S. Liechti M.E. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology 2020 45 3 462 471 10.1038/s41386‑019‑0569‑3 31733631
    [Google Scholar]
  62. Liechti M. Saur M.R. Gamma A. Hell D. Vollenweider F.X. Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000 23 4 396 404 10.1016/S0893‑133X(00)00126‑3 10989266
    [Google Scholar]
  63. MacInnes N. Handley S.L. Harding G.F. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J. Psychopharmacol. 2001 15 3 181 186 11565625
    [Google Scholar]
  64. Parrott A.C. Sisk E. Turner J.J. Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend. 2000 60 1 105 110 10821995
    [Google Scholar]
  65. Illingworth B.J. Lewis D.J. Lambarth A.T. Stocking K. Duffy J.M. Jelen L.A. Rucker J.J. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. J. Psychopharmacol. 2021 35 5 501 511 33345689
    [Google Scholar]
  66. Mitchell J.M. Bogenschutz M. Lilienstein A. Harrison C. Kleiman S. Parker-Guilbert K. Ot’alora G M. Garas W. Paleos C. Gorman I. Nicholas C. Mithoefer M. Carlin S. Poulter B. Mithoefer A. Quevedo S. Wells G. Klaire S.S. van der Kolk B. Tzarfaty K. Amiaz R. Worthy R. Shannon S. Woolley J.D. Marta C. Gelfand Y. Hapke E. Amar S. Wallach Y. Brown R. Hamilton S. Wang J.B. Coker A. Matthews R. de Boer A. Yazar-Klosinski B. Emerson A. Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 2021 27 6 1025 1033 33972795
    [Google Scholar]
  67. Rudnick G. Wall S.C. The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 1992 89 5 1817 1821 1347426
    [Google Scholar]
  68. Hake H.S. Davis J.K.P. Wood R.R. Tanner M.K. Loetz E.C. Sanchez A. Ostrovskyy M. Oleson E.B. Grigsby J. Doblin R. Greenwood B.N. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol. Behav. 2019 199 343 350 30529341
    [Google Scholar]
  69. Nardou R. Lewis E.M. Rothhaas R. Xu R. Yang A. Boyden E. Dölen G. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature 2019 569 7754 116 120 30944474
    [Google Scholar]
  70. Doss M.K. Weafer J. Gallo D.A. de Wit H. MDMA impairs both the encoding and retrieval of emotional recollections. Neuropsychopharmacology 2018 43 4 791 800 28825422
    [Google Scholar]
  71. Unützer J. Park M. Older adults with severe, treatment-resistant depression. JAMA 2012 308 9 909 918 22948701
    [Google Scholar]
  72. Tetsuka S. Depression and dementia in older adults: A neuropsychological review. Aging Dis. 2021 12 8 1920 1934 34881077
    [Google Scholar]
  73. van Marum R.J. Underrepresentation of the elderly in clinical trials, time for action. Br. J. Clin. Pharmacol. 2020 86 10 2014 2016 32909294
    [Google Scholar]
  74. Johnston C.B. Mangini M. Grob C. Anderson B. The safety and efficacy of psychedelic-assisted therapies for older Adults: knowns and unknowns. Am. J. Geriatr. Psychiatry 2023 31 1 44 53 36184377
    [Google Scholar]
  75. Breakthrough Therapy. 2018 Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
  76. Reardon S. MDMA therapy for PTSD rejected by FDA panel. Nature 2024 38844808
    [Google Scholar]
  77. Armstrong S.B. Davis A.K. Psychedelic research at a crossroads. Science 2024 385 6715 1255 39298596
    [Google Scholar]
  78. Wolfgang A.S. Hoge C.W. Psychedelic-assisted therapy in military and veterans healthcare systems: Clinical, legal, and implementation considerations. Curr. Psychiatry Rep. 2023 25 10 513 532 10.1007/s11920‑023‑01446‑4 37682446
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673359474250511181821
Loading
MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years
Bentham Science Publishers ; https://doi.org/10.2174/0109298673359474250511181821
/content/journals/cmc/10.2174/0109298673359474250511181821
/content/journals/cmc/10.2174/0109298673359474250511181821
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: literature analysis ; oxytocin ; PubMed ; scopus ; PTSD ; MDMA

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test